mk-4280
mAbexperimental
Clinical trial activity
12 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
11
Phase 3
3
Phase 4
0
Earliest trial started May 2, 2016 (NCT02720068)
Timeline
Indications
Studied for
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Carcinoma, Renal Cell · Phase 1/Phase 2
- Carcinoma, Squamous Cell · Phase 2
- Carcinoma, Transitional Cell · Phase 1/Phase 2
- Colorectal Neoplasms · Phase 3
- Endometrial Neoplasms · Phase 2
- Esophageal Neoplasms · Phase 1/Phase 2
- Hodgkin Disease · Phase 3
- Lymphoma, B-Cell · Phase 1/Phase 2
- Lymphoma, Non-Hodgkin · Phase 1/Phase 2
- Neoplasms · Phase 2
- Small Cell Lung Carcinoma · Phase 1/Phase 2
Mechanism of action
- Lymphocyte activation gene 3 proteinINHIBITOR
LAG3 inhibitor
Chemistry & pharmacology
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297784 ↗
Also known as
- mk-4280
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06036836 | Phase 2 | Sep 29, 2023 | Merck |
| NCT05845814 | Phase 1/Phase 2 (Phase 2) | Jun 23, 2023 | Merck |
| NCT05508867 | Phase 3 | Oct 18, 2022 | Merck |
| NCT05342636 | Phase 1/Phase 2 (Phase 2) | Jul 27, 2022 | Merck |
| NCT05600309 | Phase 3 | Jun 14, 2022 | Merck |
| NCT05064059 | Phase 3 | Nov 10, 2021 | Merck |
| NCT04938817 | Phase 1/Phase 2 (Phase 2) | Aug 19, 2021 | Merck |
| NCT04626518 | Phase 1/Phase 2 (Phase 2) | Dec 17, 2020 | Merck |
| NCT04626479 | Phase 1/Phase 2 (Phase 2) | Dec 17, 2020 | Merck |
| NCT03598608 | Phase 1/Phase 2 (Phase 2) | Oct 17, 2018 | Merck |
| NCT03516981 | Phase 2 | Sep 28, 2018 | Merck |
| NCT02720068 | Phase 1 | May 2, 2016 | Merck |
Showing 12 of 12 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck | For profit | 12 | 12 | 3 | 2016 |
1 organizations
Page 1 / 1